Updated Clinical Data on Ariad Pharmaceuticals, Inc.'s Investigational pan-BCR-ABL Inhibitor, Ponatinib, to Be Presented at Annual American Society of Hematology Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that updated clinical data from a fully enrolled Phase 1 trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) being held in Orlando, Florida, December 4-7, 2010. These Phase 1 findings in patients with resistant and refractory chronic myeloid leukemia (CML) will be featured in an oral presentation and will also be highlighted in a webcast investor meeting being held at ASH.